Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Lipum is looking forward to the new year

2021 was an eventful year for Lipum with several achieved milestones in the preparation for the first clinical trial with the biological drug candidate SOL-116 for the treatment of chronic inflammatory diseases. Another significant milestone during the year was, of course, the listing on Nasdaq First North Growth Market. Lipum is now looking forward to 2022 when the company enters the clinical stage, which CEO Einar Pontén tells us more about in an interview with BioStock.Read the full article at biostock.se: https://www.biostock.se/en/2022/01/lipum-is-looking-forward-to-the-new-year/

Nordea to host virtual Capital Markets Day on 17 February

Nordea invites investors and analysts to a virtual Capital Markets Day on 17 February 2022 at 12.00 EET (11.00 CET). During the day Nordea’s management will present Nordea’s strategic priorities and financial targets. As communicated earlier, Nordea plans to publish its new financial targets alongside its 2021 fourth-quarter and full-year results on 3 February 2022. Nordea’s business areas will also present their strategic agendas during the Capital Markets Day. Presentations will be followed by Q&A sessions. Please visit nordea.com/cmd  for full agenda and

Saab Awarded Indian Contract for AT4 Support Weapon

Saab’s AT4 weapon has been selected by the Indian Armed Forces through a competitive programme for a single-shot weapon. AT4 will be used by the Indian Army and the Indian Air Force.The Indian Armed Forces are a new customer for AT4. This order includes the AT4CS AST, which can be fired from confined spaces such as from inside buildings, bunkers and other urban environments. The AT4CS AST offers a tandem warhead with a breach or blast mode, which is optimised to defeat enemies within buildings and to destroy structures, which can create a point of access into them. The contract was

Invitation to presentation of Addtech's Interim Report on February 8 at 10.00 a.m (CET)

Welcome to a conference call regarding Addtech's Interim Report for the third quarter on February 8 at 10.00 a.m (CET). The conference is aimed at analysts, the media and investors and will be held in English. The presentation will be hosted by CEO Niklas Stenberg and CFO Malin Enarson. The presentation material will be available in advance here: https://www.addtech.com/investors/financial-information/presentations It will also be possible to follow the presentation on the web, see link below. The webcast will also be available afterwards via the same link. For participation in the

Fortum best Finnish listed company in European gender equality study ranking 22nd

FORTUM CORPORATON ONLINE RELEASE 20.1.2022  Fortum was ranked 22nd in the European EWoB Gender Diversity Index 2021. The study examined how gender diversity is realised in the boards and key management of European companies. The study included 668 European listed companies.   “Valuing talent from diverse backgrounds, rewarding performance, and providing equal opportunities for advancement are key principles for us at Fortum. I believe that we are more competitive and can better meet the expectations of our customers and society when there is diversity also in our management. This is

Nordea’s fourth-quarter and full-year results 2021 will be presented on Thursday 3 February 2022

The report will be published at approximately 07.30 EET (06.30 CET). Webcast at 11.00 EET (10.00 CET) Frank Vang-Jensen, President and Group CEO, will present the results followed by a Q&A audio session for investors and analysts with Frank Vang-Jensen, Ian Smith, Group CFO, and Matti Ahokas, Head of Investor Relations. To participate in the webcast, please use the webcast link  or dial one of the following numbers: •          +44 333 300 0804 •          +46 8 566 426 51 •          +358 9 8171 0310 •          +45 35 44 55 77

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 17 - 20 JANUARY 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

PHI Introduces Non-invasive Fluorescence

Phase Holographic Imaging (PHI) is currently preparing fluorescence units for its first users. The HoloMonitor add-on fluorescence unit enables medical research laboratories to analyze the all-important genetic activity of individual cells as they multiply in a cell incubator — without the detrimental effects associated with conventional fluorescence microscopy. Living cell cultures are extensively used and analyzed in over 100 000 commercial and academic research labora­tories world­wide, creating a market of up to 5 billion USD for incubator-based live-cell imaging. Most of the

Summa Equity raises the largest European impact fund to date – announcing final close of c. EUR 2.3 billion for third fund

Summa Equity is expanding to support its mission of investing to solve global challenges in line with the United Nations’ Sustainable Development Goals.Stockholm/Oslo: Today, Summa Equity  announced the closing of its third fund (“Fund III” or “the Fund”), with investor commitments of c. EUR 2.3 billion (c. SEK 23 billion). The Fund was closed in record time and was oversubscribed within four months, raised in a fully virtual fundraising environment. The capital raised will strengthen Summa Equity’s ability to contribute to solving global challenges through

NEW ORDER AND FIRST DELIVERY OF KEBNI SENSAITION

KebNi AB (publ) fulfilled delivery of another order for the SensAItion IMU (Inertial Measurement Unit) platformStockholm, 20 January 2022 – Today, Kebni announces a new order from a new client regarding the coming inertial sensing multisensor platform called SensAItion. The order is for qualifying SensAItion in a completely new use-case. To facilitate easy testing and integration, SensAItion was ordered and delivered with its comprehensive development kit. “It is exciting to see the first SensAItion unit get produced, calibrated, pass the demanding performance tests, and get shipped to

Publishing of Caverion Corporation's Financial Statement Release for 2021 on 10 February 2022

Caverion Corporation Investor News 20 January 2022 at 10.00 a.m. EETPublishing of Caverion Corporation's Financial Statement Release for 2021 on 10 February 2022 Caverion Corporation's Financial Statement Release for 2021 will be published on Thursday, 10 February 2022, at approximately 8:00 a.m. (Finnish Time, EET). The stock exchange release and presentation materials in Finnish and in English will be published at that time on the company's website at www.caverion.com/investors. Webcast news conference for investors and media Caverion will hold a news conference on the Financial

Medius and Columbus Extend Strategic Partnership with New Infor M3 Cloud Connector

Medius and Columbus extend their longstanding partnership delivering Medius innovative spend management and accounts payable automation solutions to the joint customer base using Medius in combination with the different Infor M3 ERP versions.STOCKHOLM, January 20, 2022 – Together, Medius and Columbus now offer an expanded integration connector between the Infor M3 Cloud Edition (multi-tenant) ERP system and the Medius Spend Management and Accounts Payable (AP) Automation solutions. The integration enables a smooth transition to the Infor M3 Cloud Edition for M3 customers leveraging Medius.

Waste heat from fuel cells aids sustainable operations in cold environments

myFC Lab Stories is non-regulatory information from myFC's laboratory. The texts reflect the work that the company's researchers and developers carry out in the development of the patented technology. The numbers and data in this text are not to be considered as a forecast for future revenues. An ordinary Otto engine has an efficiency of 30 percent. Fuel cells are better, more than 50% of the hydrogen gas is converted to electrical energy and the rest is transformed into heat that can be used to increase the overall efficiency of the systems. An example where the heat can be reused in a

Invitation to the presentation of Axfood’s year-end report 2021

Axfood invites investors, analysts and the press to a presentation of the year-end report 2021 at 9:30 am CET on 3 February. The report will be published at 7:00 am CET the same day.Axfood’s President and CEO Klas Balkow will present the report together with CFO Anders Lexmon. The presentation will be held in English. Time: Thursday, 3 February at 9:30 am CET To participate, please dial in:Sweden: +46 8 505 583 74The UK: +44 333 300 9267The US: +1 646 722 4904 The presentation can also be followed live via webcast at axfood.com . After the

SKF to present FY Results and updated strategic framework on 3 February

Gothenburg, 20 January 2022: SKF will present its FY 2021 Results and updated strategic framework on 3 February 2022. The year-end results for 2021 will be published at approximately 8:00 (CET). Investors, analysts and media are invited to join a webcast, which will be broadcast live in English at 9:00–10:30 (CET). To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers. Link to web event: https://www.investis-live.com/skf/61e0528c0ba3f01200044369/eadd Sweden                               +46 10 884 80 16 UK / International

Proposals of the Shareholders’ Nomination Board of Detection Technology Plc to the Annual General Meeting 2022

Detection Technology Plc company announcement 20 January 2022 at 10:00 (EET) Proposals of the Shareholders’ Nomination Board of Detection Technology Plc to the Annual General Meeting 2022 Proposal on the number of the members, on the composition, and on the Chairman of the Board of Directors The Shareholders’ Nomination Board of Detection Technology Plc (Nomination Board) proposes to the Annual General Meeting that the number of members of the Board of Directors would be six (6). The Nomination Board proposes that Carina Andersson, Richard Ingram, Pasi Koota, Henrik Roos and

Invitation to UPM’s webcast and press conference on Financial Statements for the year 2021

(UPM, Helsinki, 20 January 2022 at 10:00 EET) – UPM will publish its fourth quarter results and Financial Statements for 2021 on 27 January 2022 at 09:30-10:00 EET. After publishing the report will be available on company's website at www.upm.com . A webcast and a conference call for analysts and investors in English language begins at 13:15 EET. UPM’s financial results will be presented by the President and CEO Jussi Pesonen and CFO Tapio Korpeinen. All participants can view the webcast online at www.upm.com 

BioStock: Elicera well-positioned to thrive in 2022

The immuno-oncology company Elicera Therapeutics achieved significant accomplishment in 2021, e.g., a listing on Nasdaq First North Growth Market and raising of 62 MSEK before issue costs, making Elicera well equipped to take yet another step in its development of cancer immunotherapies. BioStock reached out to Elicera’s CEO Jamal El-Mosleh to get his thoughts on the company’s achievements during 2021 and his expectations for 2022.Read the interview with Elicera's CEO Jamal El-Mosleh at biostock.se: https://www.biostock.se/en/2022/01/elicera-well-positioned-to-thrive-in-2022/ This is

Audientes enters first phase of mass production

Audientes today announces that it has now entered the first phase of mass production of Ven™ by Audientes with the first batch of commercially saleable devices now shipped to the Indian market.Company announcement no. 1-2022 January 20, 2022 This announcement contains insider information In line with the company’s previously communicated rollout strategy, Audientes has now entered the initial phase of mass production of their self-fitting hearing aid, Ven, with the first shipment, in branded retail-ready packaging, now off the production line and in transit to India. The

Skyliner - Building the future with WICTEC facades by WICONA

Skyliner - the flagship investment of the Karimpol Group - is one of the most impressive architectural buildings in Poland, both in terms of height and the technologies used. The high-rise building was realised using solutions and technologies that meet the requirements of sustainable construction. The WICONA brand supplied WICTEC unitised facades.[En bild som visar himmel, utomhus, stad, väg Automatiskt genererad beskrivning]   The nearly 200-metre Skyliner is seventh on the list of tallest buildings in Poland. It offers 49,000 sqm of office and retail space for lease on 42

Flowscape is preparing a list change to Nasdaq

The Board of Directors of Flowscape Technology AB (“Flowscape”) today announces its intention to carry out a list change from Spotlight Stock Market to Nasdaq First North Growth Market. The process will be initiated immediatelyFlowscape is a leading PropTech company with a system for optimizing office space as well as increasing employee efficiency and well-being. Since 2016, Flowscape has been listed on the Swedish Spotlight Stock Market and in 2020 the company started its international expansion by opening sales offices in both the USA and the UK. Today, Flowscape has about 200 customers

Mandatory notification of trade

Oslo, 20 January 2022 Reference is made to the stock exchange announcements by Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") on 19 December 2022 regarding a completed private placement (the "Private Placement") where the Company allocated 17,857,143 new shares (the "New Shares") at a subscription price of NOK 14 per share (the "Subscription Price"). In connection with the Private Placement, the following persons discharging managerial responsibilities (the "Primary Insiders") were allocated New Shares in the Private Placement at the Subscription Price: · Jan

BioStock: Promore Pharma prepares phase II study

With its drug candidates, Promore Pharma targets two comprehensive patient groups whose access to pharmaceutical products is limited – wound care and scarring. The main project ensereptide is being developed to inhibit scarring, with the aim of initiating a phase IIa study in early 2022. The company's second candidate, ropocamptide, for the stimulation of healing of chronic leg ulcers, is currently undergoing product development for an upcoming phase III study. BioStock talked to Promore Pharma's CEO Jonas Ekblom to learn more.Read the full interview with Promore Pharma's CEO Jonas Ekblom

New data from NeoDynamics PULSE study accepted for presentation at major US breast imaging conference

NeoDynamics AB (Spotlight Stock Market: NEOD), a medtech company dedicated to advancing diagnosis and care of breast cancer, will present results from the PULSE study illustrating the benefits of the novel biopsy device NeoNavia in challenging axillary lymph nodes, at the SBI/ACR Breast Imaging Symposium in Savannah, Georgia, taking place on May 16-19. The symposium is held to be the most important annual meeting for US breast imaging professionals. A subgroup analysis from the ethically approved German prospective multi-center study PULSE (ClinicalTrials.gov ID: NCT03975855), shows that

There are no items matching the current filter
There are no more items matching the current filter
Back to top